{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:53:05Z","timestamp":1790754785009,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Chiles Foundation, Portland, OR"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG), Bonn, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Walter-Schulz-Foundation, Munich, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cancer immunotherapy broadly includes active immunization, as in the use of cancer vaccines, passive immunization, such as the use of adoptive cell therapy and antibodies that modulate tumor function, and immunostimulation, using antibodies and small molecules to treat malignancy by activating or unleashing an endogenous immune response against tumor cells. Currently, &amp;gt;100 different monoclonal antibodies are in use or under evaluation for use as therapeutic agents in various malignancies. Active stimulation of the host's immune system holds promise for achieving durable remission of malignant disease and represents a nontoxic method of therapy if tumor-specific effector cells can be selectively targeted. However, no active-specific treatment strategy (i.e., a therapeutic cancer vaccine) has yet found its way into the clinical armamentarium, although several promising recent reports suggest that, for follicular lymphoma, prostate cancer, and melanoma, clinical benefit was shown for the first time in randomized trials with a vaccine approach. Here, we report on the key findings of the Third Tegernsee Conference on Immunotherapy of Cancer (Feldafing, Germany, July 2\u20134, 2009) and provide short commentaries on data presented at this meeting regarding the future role of cancer vaccines, recent developments in adoptive cellular therapy, ways to improve immunotherapeutic treatment modalities (e.g., by manipulating the tumor microenvironment), and some novel targeted therapies that are well advanced in clinical testing, all of which have implications for future oncology practice.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0213","type":"journal-article","created":{"date-parts":[[2010,1,9]],"date-time":"2010-01-09T02:35:06Z","timestamp":1263004506000},"page":"112-118","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy of Cancer: Key Findings and Commentary on the Third Tegernsee Conference"],"prefix":"10.1093","volume":"15","author":[{"given":"Dominik","family":"R\u00fcttinger","sequence":"first","affiliation":[{"name":"a Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany"},{"name":"b Micromet AG, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Winter","sequence":"additional","affiliation":[{"name":"a Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja K.","family":"van den Engel","sequence":"additional","affiliation":[{"name":"a Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Hatz","sequence":"additional","affiliation":[{"name":"a Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Walter","family":"Jauch","sequence":"additional","affiliation":[{"name":"a Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Fox","sequence":"additional","affiliation":[{"name":"c Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[{"name":"d Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center, and Donald A. Adam Comprehensive Melanoma Research Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,1,8]]},"reference":[{"key":"2021122207232402900_R1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1634\/theoncologist.2008-0167","article-title":"Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today?","volume":"14","author":"Peeters","year":"2009","journal-title":"The Oncologist"},{"key":"2021122207232402900_R2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JTO.0b013e318187220f","article-title":"Targeting angiogenesis in the treatment of lung cancer","volume":"3","author":"Wheatly-Price","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2021122207232402900_R3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"The Oncologist"},{"key":"2021122207232402900_R4","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2741\/3338","article-title":"Altering regulatory T cell function in cancer immunotherapy: A novel means to boost the efficacy of cancer vaccines","volume":"14","author":"Ruter","year":"2009","journal-title":"Front Biosci"},{"key":"2021122207232402900_R5","first-page":"582","article-title":"Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies","volume":"6","author":"Korman","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"issue":"15 suppl","key":"2021122207232402900_R6","article-title":"Effect of ipilimumab treatment on 18-month survival: Update of patients with advanced melanoma treated with 10 mg\/kg ipilimumab in three phase II clinical trials [abstract 9033]","volume":"27","author":"O'Day","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","article-title":"The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy","volume":"13","author":"Smits","year":"2008","journal-title":"The Oncologist"},{"key":"2021122207232402900_R8","article-title":"A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract LBA 9]","volume":"104","author":"Schellhammer","year":"2009","journal-title":"Proc Am Urol Assoc"},{"issue":"18 suppl","key":"2021122207232402900_R9","article-title":"Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results [abstract 2]","volume":"27","author":"Schuster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122207232402900_R10","article-title":"A phase III multi-institutional randomized study of immunization with the gp100:209\u2013217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract CRA9011]","volume":"27","author":"Schwartzentruber","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e14620","article-title":"Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects with the tumor cell microenvironment [abstract e14620]","volume":"27","author":"Lu","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R12","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","article-title":"Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation","volume":"27","author":"Emens","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R13","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R14","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232402900_R15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0213","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0213","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/1\/112\/41842658\/oncolo_15_1_112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/1\/112\/41842658\/oncolo_15_1_112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:04:49Z","timestamp":1640160289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/1\/112\/6399078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,8]]},"published-print":{"date-parts":[[2010,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0213","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,1,1]]},"published":{"date-parts":[[2010,1,1]]}}}